Porda Havas assisted MicroTech Medical (Hangzhou) Co., Ltd. (2235.HK) in the successful listing of the main board of the Hong Kong Stock Exchange
Latest Update:
19 th October, 2021

On October 19, 2021, MicroTech Medical (Hangzhou) Co., Ltd. ("MicroTech Medical" or the "Company", stock code: 2235.HK, which focuses on diabetes management and provides diabetes treatment and diabetes monitoring medical equipment, today Listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "Stock Exchange").

MicroTech Medical is offering 63,529,500 H shares globally at an issue price of HK$30.50 per share. After deducting the underwriting fees and commissions and estimated expenses payable by the company for the global offering, the net proceeds from the global offering are expected to be approximately HK$1.815 billion ( Excluding over-allotment). The Company's public offering in Hong Kong has received a good response. The initially offered offer shares have been slightly over-subscribed, which is equivalent to approximately 6.79 times of the 6,353,000 Hong Kong offer shares initially available for subscription in the Hong Kong public offering; the international offering has been slightly over-subscribed, which is equivalent to The Offer is initially available for approximately 4.9 times the total number of Offer Shares available for subscription.

As the company's financial public relations consultant team, Porda Havas participated in the maintenance of domestic and foreign media relations, the design and production of listing publicity materials, and the holding of listing celebration activities during the company's listing process, helping the company to successfully list in Hong Kong.

Dr. Zheng Pan, Chairman of the Board of Directors, Executive Director and Chief Executive Officer of MicroTech Medical Devices (Hangzhou) Co., Ltd., said: "Today, MicroTech Medical's listing on the stock exchange and stepping onto the international capital stage is an important milestone for the company. Since 2011 Since its establishment in 2009, MicroTech Medical has focused on diabetes management, providing diabetes treatment and monitoring medical devices to optimize diabetes management in China and around the world. We are committed to becoming a provider of innovative solutions in the field of diabetes monitoring and treatment devices. Realizing this vision, we will continue to improve the function and quality of our products, continue to enhance our research and development capabilities, expand our global footprint and build a cloud-based big data-based diabetes management platform to benefit both the clinical and economic benefits of diabetes patients around the world."

About MicroTech Medical

MicroTech Medical focuses on diabetes management, providing diabetes treatment and diabetes monitoring medical devices to optimize diabetes management in China and globally. Founded in 2011, the company is committed to helping people with diabetes have a healthier and better life. The core product Equil patch insulin pump ("Equil") is a semi-disposable patch insulin pump. Among all insulin pump products currently approved in China, Equil is the only patch insulin pump. In addition to Equil, the company has two other categories of commercial products, continuous glucose monitoring systems and blood glucose monitoring systems, and six other product candidates in various stages of development. The company has a further improved and diversified product line under research and development, including closed-loop artificial pancreas, second-generation patch insulin pump system, AiDEX X and IVD devices.

Latest Update:
19 th October, 2021